VolitionRX Limited (NYSEAMERICAN:VNRX) Short Interest Up 225.2% in August

VolitionRX Limited (NYSEAMERICAN:VNRX) was the recipient of a significant growth in short interest during the month of August. As of August 31st, there was short interest totaling 2,224,050 shares, a growth of 225.2% from the August 15th total of 683,892 shares. Based on an average daily trading volume, of 40,219,957 shares, the days-to-cover ratio is presently 0.1 days. Approximately 17.5% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Several analysts recently commented on VNRX shares. Benchmark reaffirmed a “hold” rating on shares of VolitionRX in a report on Monday, August 17th. Maxim Group reissued a “buy” rating and issued a $4.00 price target on shares of VolitionRX in a report on Thursday, June 18th. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $28.00.

Hedge Funds Weigh In On VolitionRX

A number of hedge funds have recently bought and sold shares of the business. Virtu Financial LLC increased its position in shares of VolitionRX by 166.6% in the fourth quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock valued at $28,000 after buying an additional 67,848 shares in the last quarter. Squarepoint Ops LLC acquired a new position in shares of VolitionRX during the 4th quarter worth approximately $34,000. Jane Street Group LLC purchased a new position in shares of VolitionRX during the 4th quarter valued at approximately $28,000. Geode Capital Management LLC lifted its position in shares of VolitionRX by 9.8% during the 4th quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock valued at $246,000 after buying an additional 85,816 shares in the last quarter. Finally, Armistice Capital LLC grew its stake in VolitionRX by 10.4% in the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock valued at $6,367,000 after acquiring an additional 887,351 shares during the period. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRX Trading Down 8.8%

VNRX traded down $0.03 on Friday, reaching $0.31. The stock had a trading volume of 1,046,498 shares, compared to its average volume of 22,753,156. VolitionRX has a 12-month low of $0.31 and a 12-month high of $14.80. The business’s 50-day moving average price is $0.75 and its two-hundred day moving average price is $2.11. The company has a market cap of $4.23 million, a P/E ratio of -0.08 and a beta of 1.10.

VolitionRX (NYSEAMERICAN:VNRX) last posted its earnings results on Thursday, August 13th. The medical research company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The firm had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.41 million. As a group, analysts predict that VolitionRX will post -2.36 earnings per share for the current year.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.